AbCellera Biologics Inc

2026. g. 17. sept. 19:52 UTC

Abcellera Biologics Inc shares are trading sharply higher as call volume exceeds expectations, driven by anticipation of an upcoming oral presentation at the IMS World Congress.

2026. g. 16. sept. 20:10 UTC

Abcellera Biologics Inc has advanced during Wednesday's session, maintaining a positive trend and staying above its 20-day moving average since Tuesday's close.

2026. g. 15. sept. 23:06 UTC

Abcellera Biologics shares declined in after-market trading, reflecting broader market concerns after a drop in the New York Empire State Manufacturing Index.

2026. g. 14. sept. 20:08 UTC

Abcellera Biologics is advancing as positive sentiment from Schrödinger's licensing agreement with Tectora Therapeutics influences market activity.

2026. g. 11. sept. 23:06 UTC

Abcellera Biologics Inc. shares declined in after-market trading, with no specific company news identified. Broader inflation concerns may be influencing market sentiment.

2026. g. 10. sept. 20:07 UTC

Abcellera Biologics Inc shares are lower today, continuing a decline since Wednesday's close. The stock trades significantly below its 20-day moving average.

2026. g. 4. sept. 20:08 UTC

Abcellera Biologics Inc shares are lower today amid broader market selling pressure following a strong jobs report, despite earlier gains during the session.

2026. g. 3. sept. 23:05 UTC

Abcellera Biologics Inc shares are higher in after-market trading, supported by broader market gains amid easing interest rate hike concerns. No specific company news was identified.

2026. g. 1. sept. 20:08 UTC

Abcellera Biologics Inc shares are lower today amid broader market declines and rising oil prices, which have renewed inflation concerns and interest rate hike expectations.

2026. g. 31. aug. 23:06 UTC

Abcellera Biologics Inc shares declined in after-market hours, reflecting broader market sentiment influenced by comments on inflation and potential interest rate hikes.

2026. g. 28. aug. 23:01 UTC

Abcellera Biologics Inc shares are trading lower in after-market hours. No specific company news was identified to explain this movement.

2026. g. 26. aug. 19:56 UTC

Abcellera Biologics Inc shares are lower today, influenced by declines in the ARK Genomic Revolution ETF and broader genomic sector trends.

2026. g. 25. aug. 23:06 UTC

Abcellera Biologics Inc. shares declined slightly in after-market trading, despite remaining above their 20-day moving average after recent gains.

2026. g. 24. aug. 23:36 UTC

Abcellera Biologics Inc. is rising in after-market trading, fueled by a director's $570,000 insider purchase near its 52-week high, indicating insider confidence.

2026. g. 21. aug. 19:36 UTC

Abcellera Biologics Inc shares are lower today amid broader market pressures. The decline coincides with a drop in U.S. Treasury yields and infrastructure-related assets.

2026. g. 20. aug. 19:16 UTC

Abcellera shares lower amid broader market pressures, influenced by SPDR ETF.

2026. g. 19. aug. 23:02 UTC

Abcellera Biologics Inc shares are higher in after-hours trading, reflecting increased investor interest and social media discussions about the stock's potential at $12.20.

2026. g. 18. aug. 19:56 UTC

Abcellera Biologics Inc shares are lower, influenced by declines in small-cap stocks and rising Treasury yields amid ongoing inflation concerns.

2026. g. 17. aug. 23:06 UTC

Abcellera Biologics Inc shares are lower in after-market trading, following unusual volatility and a decline in the Russell 2000 Index.

2026. g. 14. aug. 19:44 UTC

Abcellera Biologics Inc shares are higher today amid increased call option volume and discussions of insider buying, with the stock trading around $10.50.

2026. g. 13. aug. 19:31 UTC

Abcellera Biologics priced an oversubscribed offering at $9.75 per share, aiming to raise $200 million. Shares are higher since Wednesday's close despite earlier pullback.

2026. g. 12. aug. 20:02 UTC

Abcellera Biologics has launched a $200 million public offering to support its lead program, while shares are advancing during today's trading session.

2026. g. 11. aug. 22:51 UTC

Abcellera Biologics announced a $200 million public offering, contributing to a decline in after-market trading amid investor concerns over potential dilution.

2026. g. 10. aug. 23:06 UTC

Abcellera Biologics reported positive Phase 2 trial results for ABCL635, but shares are lower in after-market hours amid broader market declines.

2026. g. 8. aug. 00:06 UTC

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are trading higher in after-market hours.

2026. g. 7. aug. 23:21 UTC

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are sharply higher in after-market trading amid positive investor sentiment.

2026. g. 6. aug. 23:06 UTC

Abcellera Biologics Inc. shares are lower in after-market trading, despite earlier reaching a session high and remaining above the 20-day moving average.

2026. g. 5. aug. 23:02 UTC

Abcellera Biologics shares are lower in after-market hours following disappointing Q2 results, with an EPS of -$0.18 and revenue of $4.1 million.

2026. g. 3. aug. 19:36 UTC

Abcellera Biologics Inc shares are higher as market sentiment improves following President Trump's cancellation of a military strike on Iran.

2026. g. 31. jūl. 19:33 UTC

Abcellera Biologics Inc is declining during Friday's session, reflecting broader biotech sector weakness amid rising yields and inflation concerns.